Our Services
Medical Information
Helpful Resources
Published on: 9/15/2026
Mild to moderate stomach pain, nausea, bloating, and constipation are common during the first month on Wegovy as the body adjusts to semaglutide, and daily discomfort can occur, especially in the days right after an injection or dose increase. However, pain that is severe, constant, worsening, or paired with vomiting, fever, or pain radiating to the back can signal pancreatitis, gallbladder problems, or a bowel obstruction and needs prompt medical attention. Several factors matter, including your dose, how quickly it was titrated, meal size and fat content, hydration, and other medications, so see below to understand more.
Because "expected side effect" and "warning sign" can feel identical in the moment, a few minutes of structured questions can help you sort out which one you are dealing with. Take a free, instant, online symptom check to clarify your symptoms and decide whether to wait it out, adjust with your prescriber, or seek urgent care.
Last reviewed for medical accuracy: 09/14/2026
Is It Normal to Have Stomach Pain on Wegovy Every Day the First Month?
If you’ve started Wegovy (semaglutide) for weight management and are experiencing frequent stomach pain, you’re not alone. Many people report gastrointestinal (GI) side effects, especially during the first month. Understanding why these symptoms occur, how long they last, and when to seek medical advice can help you manage discomfort and stay on track with your treatment.
Wegovy is a once-weekly injectable medication approved for chronic weight management. It mimics a natural hormone (GLP-1) that helps:
By acting on receptors in your gut and brain, Wegovy can reduce calorie intake and support weight loss. However, slowing gastric emptying also means your digestive system is adjusting to a new rhythm, which can lead to common side effects like stomach pain.
Clinical trials and patient reports consistently show that GI symptoms peak in the early weeks:
These effects correspond with dose escalation. Wegovy dosing typically starts at 0.25 mg weekly, increasing every 4 weeks until you reach the maintenance dose (usually 2.4 mg). As your body adapts to higher semaglutide levels, stomach discomfort can occur—often most pronounced in the first month.
Daily mild stomach pain in the first month can be a normal part of “Wegovy stomach pain after starting.” It’s your body learning to process food more slowly.
Most people find that simple dietary and lifestyle tweaks significantly reduce stomach pain as their bodies adapt.
While mild discomfort can be expected, certain symptoms warrant prompt medical attention:
Watch for warning signs:
If you experience any of the above, speak to a doctor right away. For non-urgent concerns or if you want to understand whether your symptoms are typical, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you determine if your stomach pain is likely a common side effect or something that needs in-person evaluation.
Experiencing daily stomach pain during the first month of Wegovy is a frequent, generally temporary side effect of its appetite-regulating actions. With gradual dose increases, dietary adjustments and simple self-care strategies, most people see significant relief by the end of the second month.
However, if your pain is intense, persistent or accompanied by alarming symptoms, don’t hesitate: speak to a doctor. Your health and peace of mind matter.
(References)
* Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F, Wang T, Jiang HL, Xu SN, Huang BL, Zhou HD. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev. 2022 Jun;23(6):e13435. doi: 10.1111/obr.13435. Epub 2022 Feb 22. PMID: 35194917.
* Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789. doi: 10.3389/fendo.2022.1043789. Epub 2022 Dec 7. PMID: 36568085; PMCID: PMC9770009.
* Long B, Pelletier J, Koyfman A, Bridwell RE. GLP-1 agonists: A review for emergency clinicians. Am J Emerg Med. 2024 Apr;78:89-94. doi: 10.1016/j.ajem.2024.01.010. Epub 2024 Jan 12. PMID: 38241775.
* Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals (Basel). 2024 Feb 2;17(2). doi: 10.3390/ph17020199. Epub 2024 Feb 2. PMID: 38399414; PMCID: PMC10891568.
* Long JJ, Sahi SS, Lemke AI, Na J, Garcia Valencia OA, Budhiraja P, Wadei HM, Sudhindran V, Benzo R, Clark MM, Shah M, Fipps D, Navratil P, Abdelrheem AA, Shaik AA, Duffy DJ, Pencovich N, Shah P, Kudva YC, Kukla A, Diwan TS. The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study. Endocr Pract. 2024 Oct;30(10):963-969. doi: 10.1016/j.eprac.2024.07.008. Epub 2024 Jul 16. PMID: 39025300.
* Liu L, Shi H, Shi Y, Wang A, Guo N, Tao H, Nahata MC. Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis. Pharmaceuticals (Basel). 2024 Jun 24;17(7). doi: 10.3390/ph17070828. Epub 2024 Jun 24. PMID: 39065679; PMCID: PMC11279917.
* Esparham A, Mehri A, Dalili A, Richards J, Khorgami Z. Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis. Obes Rev. 2024 Nov;25(11):e13811. doi: 10.1111/obr.13811. Epub 2024 Aug 12. PMID: 39134066.
* Austregésilo de Athayde De Hollanda Morais B, Martins Prizão V, de Moura de Souza M, Ximenes Mendes B, Rodrigues Defante ML, Cosendey Martins O, Rodrigues AM. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. J Diabetes Complications. 2024 Oct;38(10):108834. doi: 10.1016/j.jdiacomp.2024.108834. Epub 2024 Aug 20. PMID: 39178623.
* Nie Y, Zhang Y, Liu B, Meng H. Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis. Obes Surg. 2025 Mar;35(3):808-822. doi: 10.1007/s11695-025-07733-8. Epub 2025 Feb 13. PMID: 39948306.
* Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025 Aug 14;393(7):635-647. doi: 10.1056/NEJMoa2502081. Epub 2025 Jun 22. PMID: 40544433.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.